

Dentons advises Bpifrance Large Ventures in a 39M€ Series C financing round of Lyon-based biotech company ENYO Pharma

DENTONS

February 5, 2024

Dentons accompanied Bpifrance Large Ventures in a 39M€ Series C financing round of ENYO Pharma, a Lyon-based biopharmaceutical company developing innovative therapies for kidney failure-related diseases.

This transaction was co-led by OrbiMed and Morningside Ventures, with the participation of other existing investors including Andera Partners and Bpifrance InnoBio.

This financing will support the phase 2 trial of Vonafexor, a drug candidate for kidney disease, as well as operations and R&D until the first semester 2026.

The **Dentons Paris** team was composed of **Olivia Guéguen** (partner), **Pierre-Marie Gallo** (associate) and **Charlotte Berger** (associate).

About Dentons

Across over 80 countries, Dentons helps you grow, protect, operate and finance your organization by providing uniquely global and deeply local legal solutions. Polycentric, purpose-driven and committed to inclusion, diversity, equity and sustainability, we focus on what matters most to you. www.dentons.com

Your Key Contacts



Olivia Guéguen

Partner, Co-Head of Private Equity and Venture Capital, Europe and Head of Corporate M&A, France, Paris

D +33 1 42 68 49 87

olivia.gueguen@dentons.com

Media contact

Albane Helye

Business Development, Marketing, Communication & Press Relation Manager, Paris

albane.helye@dentons.com

